David Turkaly
Stock Analyst at Citizens
(2.26)
# 2,678
Out of 5,114 analysts
144
Total ratings
42.42%
Success rate
-2.8%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYK Stryker | Upgrades: Market Outperform | $440 | $355.20 | +23.87% | 4 | Dec 19, 2025 | |
| TELA TELA Bio | Maintains: Market Outperform | $7 → $5 | $1.14 | +338.60% | 7 | Nov 14, 2025 | |
| APYX Apyx Medical | Upgrades: Market Outperform | $8 | $3.49 | +129.23% | 6 | Nov 12, 2025 | |
| AXGN Axogen | Maintains: Market Outperform | $26 → $34 | $31.98 | +6.32% | 8 | Oct 30, 2025 | |
| KIDS OrthoPediatrics | Maintains: Market Outperform | $35 → $25 | $17.07 | +46.46% | 12 | Oct 10, 2025 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $112 → $73 | $65.92 | +10.74% | 9 | Aug 7, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $15.46 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $87.06 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $80.21 | +24.67% | 12 | May 20, 2025 | |
| STE STERIS | Maintains: Market Outperform | $265 → $280 | $254.34 | +10.09% | 18 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $35 → $25 | $12.65 | +97.63% | 15 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $62 → $55 | $26.76 | +105.53% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $140 → $125 | $89.13 | +40.24% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $400 → $500 | $481.28 | +3.89% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $121.89 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $20.38 | +57.02% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $7.57 | +111.36% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $1.40 | +114.29% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $9.48 | -47.26% | 1 | Oct 6, 2017 |
Stryker
Dec 19, 2025
Upgrades: Market Outperform
Price Target: $440
Current: $355.20
Upside: +23.87%
TELA Bio
Nov 14, 2025
Maintains: Market Outperform
Price Target: $7 → $5
Current: $1.14
Upside: +338.60%
Apyx Medical
Nov 12, 2025
Upgrades: Market Outperform
Price Target: $8
Current: $3.49
Upside: +129.23%
Axogen
Oct 30, 2025
Maintains: Market Outperform
Price Target: $26 → $34
Current: $31.98
Upside: +6.32%
OrthoPediatrics
Oct 10, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $17.07
Upside: +46.46%
Lantheus Holdings
Aug 7, 2025
Maintains: Market Outperform
Price Target: $112 → $73
Current: $65.92
Upside: +10.74%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $15.46
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $87.06
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $80.21
Upside: +24.67%
STERIS
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $254.34
Upside: +10.09%
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $12.65
Upside: +97.63%
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $26.76
Upside: +105.53%
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $89.13
Upside: +40.24%
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $481.28
Upside: +3.89%
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $121.89
Upside: -
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $20.38
Upside: +57.02%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $7.57
Upside: +111.36%
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.40
Upside: +114.29%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $9.48
Upside: -47.26%